Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juluca Switch Study in Virologically Suppressed Children with HIV-1
NCT05674656Phase 2Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir + rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Jul 2023; status: recruiting.
02
Drugs
dolutegravir + rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05674656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674656.